These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10906624)

  • 1. Clinical data: AVERT and QUO VADIS.
    O'Neill BJ
    Can J Cardiol; 2000 Aug; 16 Suppl E():32E-35E. PubMed ID: 10906624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial.
    Waters DD
    Can J Cardiol; 2000 Jan; 16 Suppl A():11A-3A. PubMed ID: 10653925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia.
    Oosterga M; Voors AA; Pinto YM; Buikema H; Grandjean JG; Kingma JH; Crijns HJ; van Gilst WH
    Am J Cardiol; 2001 Mar; 87(5):542-6. PubMed ID: 11230836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
    Pitt B; Waters D; Brown WV; van Boven AJ; Schwartz L; Title LM; Eisenberg D; Shurzinske L; McCormick LS
    N Engl J Med; 1999 Jul; 341(2):70-6. PubMed ID: 10395630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BANFF: an update.
    Anderson T
    Can J Cardiol; 1999 Apr; 15 Suppl B():29B-30B. PubMed ID: 10350682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atorvastatin in secondary prevention].
    Ongen Z; Yilmaz Y; Karadağ B
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():23-8. PubMed ID: 19404047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [AVERT [The Atorvastatin versus Revascularization Treatment]].
    Mokuno H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():436-41. PubMed ID: 11347110
    [No Abstract]   [Full Text] [Related]  

  • 9. Quinapril with high affinity to tissue angiotensin-converting enzyme reduces restenosis after percutaneous transcatheter coronary intervention.
    Okimoto T; Imazu M; Hayashi Y; Gomyo Y; Sekiguchi Y; Yanagihara K; Shimohara Y; Sumii K; Yamamoto H; Tadehara F; Toyofuku M; Kohno N
    Cardiovasc Drugs Ther; 2001 Jul; 15(4):323-9. PubMed ID: 11800416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.
    Pitt B; O'Neill B; Feldman R; Ferrari R; Schwartz L; Mudra H; Bass T; Pepine C; Texter M; Haber H; Uprichard A; Cashin-Hemphill L; Lees RS;
    Am J Cardiol; 2001 May; 87(9):1058-63. PubMed ID: 11348602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 (IL-6)-174 G/C polymorphism--lack of association with inflammatory and haemostatic variables in patients with coronary heart disease treated with atorvastatin and quinapril.
    Potaczek DP; Undas A; Szczeklik A
    Int J Cardiol; 2006 Sep; 112(1):123-4. PubMed ID: 16337287
    [No Abstract]   [Full Text] [Related]  

  • 12. Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).
    Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group
    BMC Pediatr; 2009 Dec; 9():79. PubMed ID: 20017932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease.
    Lauten WB; Khan QA; Rajagopalan S; Lerakis S; Rahman ST; Parthasarathy S; Khan BV
    Am J Cardiol; 2003 May; 91(9):1116-9. PubMed ID: 12714159
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT).
    McCormick LS; Black DM; Waters D; Brown WV; Pitt B
    Am J Cardiol; 1997 Nov; 80(9):1130-3. PubMed ID: 9359537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale.
    Warnica JW; Gilst WV; Baillot R; Johnstone D; Block P; Myers MG; Chocron S; Ave SD; Martineau P; Rouleau JL
    Can J Cardiol; 2002 Nov; 18(11):1191-200. PubMed ID: 12464983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is aggressive lipid-lowering therapy preferable to angioplasty in stable coronary artery disease?
    Ellis PM
    Med J Aust; 2001 Nov; 175(9):492-3. PubMed ID: 11758081
    [No Abstract]   [Full Text] [Related]  

  • 18. [Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
    Ostroumova OD
    Kardiologiia; 2002; 42(3):99-104. PubMed ID: 12494197
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature.
    Blumenthal RS; Cohn G; Schulman SP
    J Am Coll Cardiol; 2000 Sep; 36(3):668-73. PubMed ID: 10987582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.